Mike Hannay Aug 2016 WebA former Vice President of AstraZeneca has been appointed to a key national health role - less than a year after joining the NHS.

Professor Mike Hannay is to take up the position of Chair of the national AHSN Network, a collaborative of England’s 15 Academic Health Science Networks (AHSNs). Mike was previously the Vice-chair of the Network.

Mike’s new role will operate alongside his current position as Managing Director of the East Midlands AHSN, a post he took up in July 2016.

AHSNs were established by the NHS in 2013 with a remit to work across health, social care, academia and industry to speed up the adoption and spread of innovation. Since 2013 more than 200 innovations have been introduced through AHSN influence benefiting over 6 million patients and leveraging £330 million investment.

The NHS recently announced that AHSNs will be relicensed for a further period from April 2018, and will continue to operate as a key innovation delivery arm for the NHS.

As Chair of the AHSN Network, Mike will play a central role in supporting the AHSNs through the current relicensing process, and an important focus will be to continue to develop national collaboration between health and industry bodies.

Mike has over 25 years’ national and international experience within the pharmaceutical industry, with a track record of building collaboration with healthcare and academia. Previous roles include ThermoFisher Scientific (Vice President for the UK BioPharma Services Division) and AstraZeneca (Vice President of Medicines Development).

Mike takes on the role from Dr Liz Mear, who is Chief Executive of the Innovation Agency. She has served as Network Vice-Chair from November 2015 and as Chair from January 2016.

“Liz’s commitment to the Network has been outstanding and I would like to thank her on behalf of the AHSN chief officers,” said Mike. “All 15 AHSNs can approach our new licence period with confidence and Liz has played a central role in building our collective reputations and developing our collaborative working.”

“I’m honoured to take up the position of Chair of the AHSN Network,” said Mike. “We will continue to act as the connective tissue across organisations and sectors; harnessing the enthusiasm and passion of frontline health staff and unlocking the potential for health, commercial and third sector innovators to improve services and save money.

AHSNs will create exciting opportunities to expand our national collaboration with industry as we collectively deliver NHS programmes and contribute to the adoption and spread of products and services developed by commercial innovators.”

Mike added: “The NHS is facing enormous challenges and Academic Health Science Networks have important roles to play in supporting our health and industry partners to transform services for patients throughout England. During our first licence, we have delivered improved clinical outcomes and better patient experiences, reducing the cost of care and stimulating wealth creation.”

The Office for Life Sciences recently confirmed that AHSNs will coordinate ‘Innovation Exchanges’ so that innovative new diagnostic tools, treatments and medical technologies reach patients faster. Innovation Exchanges are one of the key outcomes of the Accelerated Access Review (AAR), an independent report commissioned by the government and published in 2016. AHSNs will share £39m in order to deliver Innovation Exchanges.

Mike lives in Derby and is married with two grown-up children. The Network Chair serves for one year, and Mike takes up the role from 20 September.

- ends -

About the Academic Health Science Networks (AHSNs):

The NHS has huge potential to be creative but the system is slow to adopt innovation: AHSNs exist to speed up this process. Set up by the NHS in 2013 with an initial 5 year licence, England’s 15 AHSNs build collaboration across sectors, acting as ‘honest brokers’ to drive the adoption and spread of innovation at pace and scale; and in so doing to stimulate economic growth.

Based on their significant positive impacts, NHS England has published its intention to relicense the AHSNs for a further period starting from April 2018. For example, during their first licence period, the combined impacts achieved by the AHSNs include:

- Introducing more than 200 innovations across 11,000 sites, which have benefited an estimated over 6 million patients

- Leveraging £330 million investment for the nation

- Supporting the creation of over 500 jobs.

For more about the AHSNs visit and for a selection of AHSN-supported projects visit the Atlas of Innovations at

Media enquiries: for further background to Mike’s career – along with a photo – contact Chris Taylor on 0115 748 4242 This email address is being protected from spambots. You need JavaScript enabled to view it. or Lucy Hose on 0115 748 4243 This email address is being protected from spambots. You need JavaScript enabled to view it.